Figure 5 | Cell Death & Disease

Figure 5

From: Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies

Figure 5

Combination of I-BET762 with obatoclax increases apoptosis in rituximab/chemoresistant B-cell lymphomas. (a and b) Human Raji-4RH and RL-4RH were treated with indicated concentrations of obatoclax or I-BET762 for 240 h. Apoptosis was assessed by flow cytometric analysis of TMRE, surface exposure of phosphotidylserine (annexin V staining) and cell-cycle analysis. Each point represents the mean ±S.E. value of three individual experiments, *P<0.05. (c) Western blot analysis on whole-cell lysates prepared from the human Raji-4RH and Rl-4RH lymphomas treated for 72 h with the single agents or in combination. The expression of indicated proteins was detected with specific antibodies and loading normalization was confirmed by GAPDH probing

Back to article page